| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/14/2023 | 2008.22% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 10/08/2020 | 2008.22% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 09/09/2020 | 4116.44% | HC Wainwright & Co. | $24 → $6 | Maintains | Buy |
| 09/08/2020 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | RBC Capital | Downgrades | Outperform → Sector Perform | |
| 06/17/2020 | 15360.3% | BTIG | → $22 | Initiates Coverage On | → Buy |
| 06/04/2020 | 22387.7% | Nomura | $12 → $32 | Maintains | Buy |
| 03/26/2020 | 78606.96% | Nomura | → $112 | Initiates Coverage On | → Buy |
| 04/05/2019 | 12549.33% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 03/19/2019 | 19576.74% | Oppenheimer | → $28 | Initiates Coverage On | → Outperform |
| 12/26/2018 | 16765.78% | HC Wainwright & Co. | → $24 | Initiates Coverage On | → Buy |
| 12/07/2018 | 16063.04% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
| 10/24/2018 | 15360.3% | B. Riley Securities | → $22 | Initiates Coverage On | → Buy |
| 09/14/2018 | 25198.66% | Cantor Fitzgerald | $32 → $36 | Maintains | Overweight |
What is the target price for Corbus Pharmaceuticals (CRBP)?
The latest price target for Corbus Pharmaceuticals (NASDAQ: CRBP) was reported by HC Wainwright & Co. on February 14, 2023. The analyst firm set a price target for $3.00 expecting CRBP to rise to within 12 months (a possible 2008.22% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corbus Pharmaceuticals (CRBP)?
The latest analyst rating for Corbus Pharmaceuticals (NASDAQ: CRBP) was provided by HC Wainwright & Co., and Corbus Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Corbus Pharmaceuticals (CRBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on February 14, 2023 so you should expect the next rating to be made available sometime around February 14, 2024.
Is the Analyst Rating Corbus Pharmaceuticals (CRBP) correct?
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $0.00 to $3.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $0.14, which is within the analyst's predicted range.